{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:22:18Z","timestamp":1787008938890,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase (JAK) inhibitors tofacitinib and upadacitinib are effective therapies for inflammatory bowel disease and rheumatologic disorders but currently possess a warning for increased venous thromboembolism (VTE) risk. Some patients with a history of VTE may benefit from a JAK inhibitor, but the risk of recurrent VTE with JAK inhibitor use is unclear. Our goal was to observe rates of new VTE events after starting JAK inhibitor therapy in patients with a prior VTE, and observe whether concurrent anticoagulation (AC) reduces this risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a review of adults prescribed tofacitinib or upadacitinib between January 1, 2000, and June 30, 2023, with a prior history of VTE. Patient charts were reviewed for demographic data, disease type, and VTE date(s), and to verify duration of JAK inhibitor use along with any concurrent AC. VTEs following JAK inhibitor initiation were identified by International Classification of Diseases\u2013Tenth Revision code and verified by physician documentation and imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 79 patients with a documented VTE history before initiating JAK inhibitors, 47 of whom began a JAK inhibitor with concurrent AC. Of these, 15 patients discontinued AC while receiving JAK inhibitors. In total, 5 new VTE events were observed during 55.42 patient-years of JAK inhibitor treatment without concurrent AC (9.0 events per 100 patient-years), while no new VTE events occurred during 65.2 patient-years of JAK inhibitor treatment with concurrent AC, demonstrating a lower risk of recurrent VTE (P\u2005=\u2005.020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that for patients with a prior VTE history there is a high risk for recurrent VTE while receiving JAK inhibitors. Concurrent use of AC with JAK inhibitors appears to be protective against recurrent VTEs in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izae100","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T18:54:59Z","timestamp":1712948099000},"page":"725-732","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5531","authenticated-orcid":false,"given":"Jeffrey A","family":"Lowell","sequence":"first","affiliation":[{"name":"Department of Medicine, Zucker School of Medicine at Hofstra University, Northwell Health , Manhasset, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garvita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Preclinical Medicine, Arkansas College of Osteopathic Medicine , Fort Smith, AR ,","place":["USA"]},{"name":"The Feinstein Institutes for Medical Research, Northwell Health , Manhasset, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3495-012X","authenticated-orcid":false,"given":"Arun","family":"Swaminath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Lenox Hill Hospital, Northwell Health , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northwell Health, Zucker School of Medicine at Hofstra\/Northwell , Manhasset, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"12","key":"2025030423093339100_CIT0001","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3748\/wjg.v20.i12.3173","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment","volume":"20","author":"Papa","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"9715","key":"2025030423093339100_CIT0002","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet."},{"issue":"47","key":"2025030423093339100_CIT0003","doi-asserted-by":"publisher","first-page":"E1438","DOI":"10.1503\/cmaj.161485","article-title":"Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-\u03b1 inhibitors or nonbiologic agents: a cohort study","volume":"189","author":"Desai","year":"2017","journal-title":"CMAJ."},{"issue":"3","key":"2025030423093339100_CIT0004","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1055\/s-0037-1615600","article-title":"The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study","volume":"85","author":"Bernstein","year":"2001","journal-title":"Thromb Haemost."},{"issue":"3","key":"2025030423093339100_CIT0005","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-014-2492-7","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"33","author":"Ungprasert","year":"2014","journal-title":"Clin Rheumatol."},{"issue":"3","key":"2025030423093339100_CIT0006","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"2025030423093339100_CIT0007","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"2025030423093339100_CIT0008","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"issue":"1","key":"2025030423093339100_CIT0009","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol."},{"issue":"4","key":"2025030423093339100_CIT0010","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf."},{"issue":"3","key":"2025030423093339100_CIT0011","doi-asserted-by":"publisher","first-page":"103504","DOI":"10.1016\/j.autrev.2023.103504","article-title":"Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study","volume":"23","author":"Solitano","year":"2023","journal-title":"Autoimmun Rev."},{"issue":"10","key":"2025030423093339100_CIT0012","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2025030423093339100_CIT0013","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025030423093339100_CIT0014","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1389450121666200902164240","article-title":"Thrombosis in IBD in the Era of JAK inhibition","volume":"22","author":"Solitano","year":"2021","journal-title":"Curr Drug Targets."},{"issue":"2","key":"2025030423093339100_CIT0015","doi-asserted-by":"publisher","first-page":"e002571","DOI":"10.1136\/rmdopen-2022-002571","article-title":"Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors","volume":"8","author":"Weitz","year":"2022","journal-title":"RMD Open"},{"issue":"Suppl 1","key":"2025030423093339100_CIT0016","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2022-eular.1238","article-title":"POS0519 relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or tnf inhibitors: a post hoc analysis of oral surveillance","volume":"81","author":"Karpouzas","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2025030423093339100_CIT0017","doi-asserted-by":"publisher","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"2025030423093339100_CIT0018","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"2025030423093339100_CIT0019","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.mayocp.2020.12.035","article-title":"Janus kinase inhibitors and risk of venous thromboembolism: a systematic review and meta-analysis","volume":"96","author":"Bilal","year":"2021","journal-title":"Mayo Clin Proc."},{"issue":"5","key":"2025030423093339100_CIT0020","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2025030423093339100_CIT0021","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology."},{"issue":"11","key":"2025030423093339100_CIT0022","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","article-title":"Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review","volume":"40","author":"Mori","year":"2021","journal-title":"Clin Rheumatol."},{"issue":"4","key":"2025030423093339100_CIT0023","doi-asserted-by":"publisher","first-page":"e003392","DOI":"10.1136\/rmdopen-2023-003392","article-title":"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"9","author":"Charles-Schoeman","year":"2023","journal-title":"RMD Open"},{"issue":"23 Suppl 1","key":"2025030423093339100_CIT0024","doi-asserted-by":"publisher","first-page":"I9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation."},{"issue":"8","key":"2025030423093339100_CIT0025","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol."},{"issue":"Suppl 1","key":"2025030423093339100_CIT0026","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/annrheumdis-2022-eular.1016","article-title":"POS0239 risk of venous thromboembolic events in patients with rheumatoid arthritis aged \u226550 years with \u22651 cardiovascular risk factor: results from a phase 3b\/4 randomised study of tofacitinib vs tumour necrosis factor inhibitors","volume":"81","author":"Charles-Schoeman","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"9757","key":"2025030423093339100_CIT0027","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/S0140-6736(10)60962-2","article-title":"Risk assessment for recurrent venous thrombosis","volume":"376","author":"Kyrle","year":"2010","journal-title":"Lancet."},{"issue":"5","key":"2025030423093339100_CIT0028","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol."},{"issue":"8","key":"2025030423093339100_CIT0029","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2025030423093339100_CIT0030","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2025030423093339100_CIT0031","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2025030423093339100_CIT0032","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1007\/s12325-020-01303-3","article-title":"Comparative efficacy of JAK Inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis","volume":"37","author":"Pope","year":"2020","journal-title":"Adv Ther."},{"issue":"4","key":"2025030423093339100_CIT0033","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5312\/wjo.v5.i4.504","article-title":"Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis","volume":"5","author":"Lundquist","year":"2014","journal-title":"World J Orthop"},{"issue":"10188","key":"2025030423093339100_CIT0034","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet."},{"key":"2025030423093339100_CIT0035","author":"Food and Drug Administration"},{"key":"2025030423093339100_CIT0036","author":"European Medicines Agency"},{"issue":"3","key":"2025030423093339100_CIT0037","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41575-022-00722-7","article-title":"Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance","volume":"20","author":"Danese","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"2025030423093339100_CIT0038","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10067-022-06415-5","article-title":"Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box","volume":"42","author":"Misra","year":"2023","journal-title":"Clin Rheumatol."},{"issue":"3","key":"2025030423093339100_CIT0039","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae100\/57403092\/izae100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/3\/725\/57403092\/izae100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/3\/725\/57403092\/izae100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:10:39Z","timestamp":1741111839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/3\/725\/7664665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,4]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae100","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,5,4]]}}}